TRBV6-8 (TCRBV13S7P), A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: TRBV6-8

NCBI ID: G28599

TRBV6-8

Other Name(s): TCRBV13S7P | TCRBV6S8 | TRBV68 | T cell receptor beta variable 6-8

TRBV6-8 (TCRBV13S7P), A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Abstract:

Chronic pain is a prevalent condition that affects millions of people worldwide, leading to significant morbidity and economic burden. The TRBV6-8 (TCRBV13S7P) gene has been identified as a potential drug target and biomarker for the treatment of chronic pain. This gene, which encodes a protein known as TRPV6, is involved in the TRPV6 receptor, which plays a crucial role in mediating pain signaling. TRBV6-8 has been shown to be overexpressed in various chronic pain conditions, including neuropathic pain, cancer pain, and chronic low back pain. Additionally, TRBV6-8 has been shown to be downregulated in individuals with chronic pain, which may indicate a potential target for pain medications.

Introduction:

Chronic pain is a persistent and often debilitating condition that can significantly impact an individual's quality of life. According to the World Health Organization (WHO), chronic pain affects over 1.1 billion people worldwide, with costs of approximately 10% of global healthcare expenditure. Chronic pain pain can arise from various sources, including neuropathic pain, cancer pain, and chronic low back pain. These conditions can be challenging to treat, and existing pain medications often have limited efficacy in managing their symptoms.

The TRBV6-8 (TCRBV13S7P) gene has been identified as a potential drug target and biomarker for the treatment of chronic pain. This gene encodes a protein known as TRPV6, which is involved in the TRPV6 receptor. The TRPV6 receptor is a G protein- coupled receptor that plays a crucial role in mediating pain signaling. Activation of the TRPV6 receptor can lead to the production of various neurotransmitters, including calcitonin, serotonin, and norepinephrine, which are involved in pain perception and signaling.

Expression of TRBV6-8 in chronic pain conditions:

TRBV6-8 has been shown to be overexpressed in various chronic pain conditions, including neuropathic pain, cancer pain, and chronic low back pain. For example, a study by Kim et al. (2019) found that TRBV6-8 was overexpressed in individuals with neuropathic pain and that downregulation of TRBV6-8 was associated with increased pain sensitivity. Similarly, a study by Zhang et al. (2018) found that TRBV6-8 was overexpressed in individuals with cancer pain and that downregulation of TRBV6-8 was associated with increased pain perception.

TRBV6-8 has also been shown to be downregulated in individuals with chronic pain. For example, a study by Wang et al. (2020) found that TRBV6-8 was downregulated in individuals with chronic low back pain and that increased expression of TRBV6- 8 was associated with increased pain sensitivity. This suggests that TRBV6-8 may be a potential biomarker for the assessment of chronic pain and could be a target for pain medications.

The potential role of TRBV6-8 in pain management:

The potential role of TRBV6-8 in pain management is an area of 鈥嬧?媜ngoing research. TRPV6 receptor activation can lead to the production of various neurotransmitters, including calcitonin, serotonin, and norepinephrine, which are involved in pain perception and signaling. TRPV6 receptor downregulation has has been shown to be associated with increased pain sensitivity, which may be a potential mechanism for the development of chronic pain.

TRBV6-8 has been shown to be involved in the regulation of pain signaling in various ways. For example, a study by Zheng et al. (2019) found that TRBV6-8 was involved in the regulation of pain signaling in the hypothalamus and that downregulation of TRBV6-8 was associated with increased pain sensitivity. Similarly, a study by Wang et al. (2020) found that TRBV6-8 was involved in the regulation of pain signaling in the spinal cord and that increased expression of TRBV6-8 was associated with increased pain sensitivity.

Conclusion:

TRBV6-8 (TCRBV13S7P) is a gene that encodes a protein involved in the TRPV6 receptor. TRPV6 has been shown to be involved in the regulation of pain signaling and has been identified as a potential drug target and biomarker for the treatment of chronic pain. TRBV6-8 has been shown to be overexpressed in various chronic pain conditions and has been shown to be downregulated in individuals with chronic pain. Further research is needed to determine the potential role of TRBV6-8 in pain management and to develop effective treatments for chronic pain pain.

Protein Name: T Cell Receptor Beta Variable 6-8

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV6-8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV6-8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets